Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.81 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | CSF1R | P07333 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5630096 | 0.96 | MAPK14 (0.87) | MAPK14HSPB1CYP2C9MAPK11LCK | |
| SCHEMBL26622697 | 0.90 | MAPK14 (0.70) | MAPK14HSPB1CYP2C9MAPK11LCK | |
| SCHEMBL3090782 | 0.89 | MAPK14 (1.00) | MAPK14HSPB1CYP2C9MAPK11LCK | |
| SCHEMBL3091601 | 0.89 | MAPK14 (0.76) | MAPK14HSPB1CYP2C9MAPK11LCK | |
| SCHEMBL26622703 | 0.89 | MAPK14 (0.68) | MAPK14HSPB1CYP2C9MAPK11LCK | |
| SCHEMBL26622758 | 0.89 | MAPK14 (0.68) | MAPK14HSPB1CYP2C9MAPK11LCK | |
| SCHEMBL5109773 | 0.88 | MAPK14 (0.75) | MAPK14HSPB1CYP2C9MAPK11LCK | |
| SCHEMBL13146376 | 0.88 | MAPK14 (0.79) | MAPK14HSPB1CYP2C9MAPK11LCK | |
| SCHEMBL12345243 | 0.88 | MAPK14 (0.69) | MAPK14HSPB1CYP2C9MAPK11LCK | |
| SCHEMBL31367847 | 0.87 | MAPK14 (0.74) | MAPK14HSPB1CYP2C9MAPK11LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208629-B2 | 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-04-24 | — | — | US | disclosed |
| US-20040267012-A1 | 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267012-A1 | 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK4, GRK4, NR4A1 | MAPK14 28/4885HSPB1 3656/4885CYP2C9 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.